Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
8%
Ph phase_1
8
67%
Ph phase_2
3
25%

Phase Distribution

8

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
8(66.7%)
Phase 2Efficacy & side effects
3(25.0%)
Phase 3Large-scale testing
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

11 of 11 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(11)
Other(1)

Detailed Status

Completed11
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (66.7%)
Phase 23 (25.0%)
Phase 31 (8.3%)

Trials by Status

unknown18%
completed1192%

Recent Activity

0 active trials
Showing 5 of 12
unknownphase_2

VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia

NCT00354276
completedphase_3

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00112554
completedphase_2

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

NCT00282022
completedphase_1

VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

NCT00304005
completedphase_1

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

NCT00025129
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT00354276Phase 2

VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia

Unknown
NCT00112554Phase 3

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

Completed
NCT00282022Phase 2

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

Completed
NCT00304005Phase 1

VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders

Completed
NCT00025129Phase 1

VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas

Completed
NCT00049699Phase 1

VNP40101M in Treating Patients With Advanced or Metastatic Cancer

Completed
NCT00083187Phase 2

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

Completed
NCT00070538Phase 1

VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies

Completed
NCT00098436Phase 1

Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias

Completed
NCT00049686Phase 1

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

Completed
NCT00098761Phase 1

VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors

Completed
NCT00840684Phase 1

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12